Stock Groups

Does Sonoma Pharmaceuticals Deserve a Place in Your Portfolio? By StockNews

by Mike Robinson

[ad_1]

© Reuters. Is Sonoma Pharmaceuticals a Good Choice for Your Portfolio?

Sonoma Pharmaceuticals (SNOA), a healthcare company, has been creating innovative products. However, it posted disappointing financials for the first quarter. So, let’s find out if it is wise to add the stock to your portfolio now.Global healthcare leader Sonoma Pharmaceuticals, Inc.’s (SNOA) shares soared to hit their 52-week high of $15.19 on December 11, 2020, after entering into an exclusive partnership with Crown Laboratories in connection to its Microcyn skincare products. However, the stock has lost 9.3% over the past month and 22.8% over the past three months to close Friday’s trading session at $5.67.

The company’s stock is volatile. It also posted disappointing financial results for the first fiscal quarter. The company reported losses for the quarter and saw its top line shrink. Its debt may increase in the coming months. So, SNOA’s near-term prospects look bleak.

Here’s what could influence SNOA’s performance in the upcoming months:

Continue reading on StockNews

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]